Preferred Label : RET Inhibitor FHND5071;
NCIt definition : An orally bioavailable selective inhibitor of the proto-oncogene receptor tyrosine
kinase rearranged during transfection (RET), with potential antineoplastic activity.
Upon oral administration, RET inhibitor FHND5071 selectively targets and binds to
wild-type RET and various RET fusions and mutations, thereby inhibiting the activity
of RET. This results in an inhibition of cell growth of tumors that exhibit increased
RET activity due to these fusions and mutations. RET overexpression, activating mutations,
and fusions result in the upregulation and/or overactivation of RET tyrosine kinase
activity in various cancer cell types. Dysregulated RET activity plays a key role
in the development and progression of certain cancers. FHND5071 is able to cross the
blood-brain barrier (BBB).;
Molecule name : FHND 5071; FHND-5071;
NCI Metathesaurus CUI : CL1907558;
Origin ID : C200562;
UMLS CUI : C5854569;
Semantic type(s)
- concept_is_in_subset
- has_target
